Requirements for complement and/or antibody for opsonization were assessed for 34 strains of Pseudomonas aeruginosa. Included were mucoid strains from patients with cystic fibrosis (CF), non-mucoid derivatives of these strains, and non-CF strains with classical morphology. Non-CF strains are known to vary as to opsonic requirements, but this study shows that mucoid strains are also diverse. Among the 14 mucoid strains, five could not be opsonized and completely resisted phagocytosis. All non-mucoid strains can be opsonized. When the bacteria were incubated in fresh human serum and stained with fluorescein, conjugated anti-C3 non-opsonizable strains did not bind C3 on the surface whereas five of six mucoid strains, which could be opsonized by complement alone, stained with anti-C3. In mucoid strains, surface characteristics correlate with differences in functional requirements for opsonization. In non-CF strains this specificity was not seen. Most mucoid strains required an intact classical complement pathway for opsonization. A number of mucoid strains could not be opsonized in the absence of a functional alternative complement pathway whereas in contrast, non-CF strains were not greatly affected by inactivation of the alternative pathway.
PMN, polymorphonuclear leukocyte
Colonization of the upper and middle airway with Pseudomonas aeruginosa is commonly encountered in patients with CF. In patients with C F who have advanced respiratory disease, isolates of P. aeru,ginosa frequently have a mucoid colonial morphology when grown on solid media (I 1, 14) . These isolates of MPA are not eradicated from the respiratory tracts of patients with CF by antibiotic therapy, and they persist in the presence of serum antibody to P. aeruginosa (6, 8) . It was recently demonstrated in our laboratory that certain strains of MPA are resistant to opsonization, compared with non-mucoid strains derived from these mucoid strains (2) . These studies employed rabbit antisera specific for the seven immunotypes according to the procedure of Fisher et al. (7) . Eight MPA strains were used for comparison with their NMPA selected from 30 original strains by two criteria: (1) they were typable by agglutination according to the immunotype scheme of Fisher et al. and ( 2 ) they could not be killed in vitro unless antiserum and PMN were present. Strains were thus excluded if there was ingestion and killing of 290% of the initial inoculum by PMN; or by PMN and C together; or, if they were killed, by C plus AS without PMN. In that study the conclusion was that MPA strains which were not killed in the presence of PMN and C, were then relatively resistant to antibody opsonization compared with NMPA strains derived from the same strains. It was hypothesized that this was due to interference of antibody attachment by the mucoid material. Strains opsonized by C alone were not further studied in detail in that study. In the study alluded to, preliminary studies of complement activation were reported. By inhibition assays, two MPA strains appeared to activate alternative complement pathway. We now report the details of opsonic requirements of these MPA strains, especially their complement binding, and compare them with their NMPA derivatives and conventional, CPA isolated from patients who did not have CF.
MATERIALS AND METHODS
Pseudomonas aeruginosa strains. MPA were isolated from sputum cultures of children seen at the Cystic Fibrosis Center at the Yale-New Haven Hospital, New Haven, CT, and were identified as such in the Clinical Microbiology Laboratory. Nonmucoid derivatives of these strains were obtained by repeatedly subculturing the mucoid strains on Mueller-Hinton agar and isolating morphologically recognizable non-mucoid colonies. P. aeruginosa isolates from non-CF patients were obtained from hospitalized pediatric and adult patients with infections due to these isolates and had classical morphology. These were isolates from a previous study at Walter Reed Army Medical Center and are designated CPA strains (1). All strains were lyophilized in skim milk. They have been shown by serial photographs to retain morphologic colonial characteristics for several years by this method (unpublished studies). The strains used in this study were all typed by agglutination with rabbit antisera according to the scheme of Fisher et al. (7) ; however, the MPA strains could not be accurately typed by this method until they changed to NMPA as previously reported (2) .
Rabbit antisera to immunotype strains. Rabbit antisera were obtained by IV immunization of young adult rabbits with whole, live organisms of each of the seven immunotype strains according to the schedule previously published (1). These strains were obtained from Parke, Davis and Co., Detroit, MI.
Opsonophagocytic assay. The method of Baltimore and Mitch-el1 (2) was used to measure opsonization. Plate-grown organisms were inoculated into shaking cultures in Mueller Hinton broth and incubated until they reached an optical density that corresponds to 4 x 10' cfu/ml, at which time they were in the logphase of growth. Ten milliliters of the culture were removed, centrifuged at 12,000 x g for 10 min, and resuspended in 10 ml of MEM (Microbiological Associates, Bethesda, MD). In the studies of complement inhibition, Hank's balanced salt solution without calcium or magnesium (Gibco Laboratories, Grand Island, NY) was used as a diluent.
In 12 x 75 mm polypropylene tubes (Falcon Plastics, Los Angeles, CA), 0.5 ml were added of a mixture containing 0.3 ml of the PMN suspension (--lo7 PMN), obtained by dextran sedimentation of heparinized whole human blood from a normal adult volunteer, 0.05 ml of antiserum, 0.05 ml of complement, 0.05 ml of the bacterial suspension containing 2 x lo7 cfu, and 0.05 ml of MEM. In addition, four control tubes were included in each test: one in which antiserum was omitted, one in which complement was omitted, one in which PMN was omitted, and one in which both antiserum and complement were omitted. In these tubes MEM replaced the omitted component. The tubes were incubated at 37°C for 60 min with end-over-end rotation by a Fisher Roto-Rack (Fisher Scientific, Pittsburgh, PA).
At the beginning of the incubation of the opsonic test and after 60 min of incubation, samples (0.05 ml) were removed from the tubes. These aliquots were diluted 1:100 in distilled water, which produced lysis of PMN and release of bacteria, and dilution colony counts were made on Mueller-Hinton agar plates. Total colony counts representing intra-and extracellular bacteria were performed after incubation overnight. Results were expressed as loglo cfu reduction according to the formula loglo (cfu at 0 min/cfu at 60 min). A loglo cfu reduction of r 1.0 (equivalent to 290% killing of bacteria in 60 min) was considered to be evidence of significant opsonization. Pseudomonas aeruginosa ingested by PMN are quickly killed so cfu reduction is an accurate estimate of opsonization (2, 15) . A positive control run simultaneously in which PMN, C, and AS were present must have 2 1.0 loglo cfu reduction for the test to be considered valid. In cases where the test strain was not opsonized by C plus AS the control was another strain and homologous antiserum tested with the same PMN and C.
Complement. The source of complement was fresh serum from a normal adult volunteer. The serum was absorbed with whole live organisms of the strain to be tested by the method of Kasper and Wyle (10) . The serum was absorbed at 4°C for I h, centrifuged at 12,000 x g for 2 min, reabsorbed at 4°C for 1 h, centrifuged in a cold room and then filter-sterilized. Complement-dependent opsonophagocytic assays were included as a positive control to demonstrate that activity remains after absorption.
Inhibition of the alternative complement pathway was accomplished by absorption with zymosan (4). Zymosan (50 mg/ml) was suspended in veronal buffered saline, pH 7.4. This suspension was boiled for I h then washed twice with saline. The fresh human serum absorbed with the test strain was then absorbed twice with 2 mg of zymosan per 1.0 ml of serum (0.04 ml of the above suspension) by incubating the serum for 60 min at 15-17°C with constant shaking. With each absorption 0.02 ml of 1 M MgCI, is added. After each absorption the mixture is centrifuged for 30 min at 12,000 x g at 4°C. The supernatant is removed and stored on ice until used.
Inhibition of the classical complement pathway was accomplished by the addition ofO.0 1 M EGTA by the method described by Johnston et al. (9) .
Fluorescent staining methods. Strains of P. aeruginosa were grown in log-phase as for the opsonophagocytic assays. A mixture containing 2 x lo7 cfu of bacteria, and 10% complement in a total volume of 0.5 ml was placed into a 12 x 75 mm polypropylene tube. This mixture was incubated at 37°C for 30 min with end-over-end rotation. For experiments in which the effect of antibody-containing serum was tested, the tubes contained 2 X lo7 cfu, 10% complement, and 10% rabbit antiserum to the homologous immunotype strain.
At the end of the 30-min incubation, the mixture was centrifuged for 2 min at 12,000 x g and resuspended in 0.5 ml of MEM. A drop of the suspension was placed on each slide to be stained and then air-dried. These slides were stained with either fluorescein isothiocyanate-conjugated sheep antiserum to rabbit immunoglobulin (Wellcome Reagents, Triangle Park, NC), goat antiserum to human C4 (Atlantic Antibodies, Westbrook, ME), or goat antiserum to human C3 (Hyland, Travenol Laboratories, Costa Mesa, CA). Each was diluted to a ratio of 1 :40. The slides were stained for 20 min in a moist chamber at 37°C and washed three times with phosphate buffered saline. The slides were scanned at x 1000 using a fluorescence microscope and fluorescence was recorded. These observations were made with the slides coded and the observer blind to which organisms and which antiserum were on the slide.
Statistical analysis. Significant difference of binding complement on the surface of bacterial stains with different opsonic requirements was determined by the use of the Fisher exact test (two-taiied).
RESULTS

Immunofluorescencec
Outlines of the bacteria could be seen easily when stained with antLC3 ( Fig. 1 ) or antLC4 ( Fig. 2 ), but they were not as bright as bacteria stained with anti-rabbit immunoglobulin (Fig. 3 ). There was no non-specific binding of fluorescent antisera. For these negative controls, each P. aeruginosa strain was incubated with saline and no complement or antiserum. No bacteria were visible and the backgrounds were dark; therefore, we scored fluorescence as either positive or negative although there was a considerable difference in qualitative brightness of the fluorescence.
In these studies a total of 34 strains, all typable, were tested for binding of C3 and C4. There were 14 MPA strains, 1 I NMPA strains and 9 CPA strains.
Immunofluorescence with anti-C3 and anti-C4. All of the strains were tested for binding of C3 and C4 in the presence of C and C plus AS. Of the 14 MPA strains, five (35.7%) bound C3; four of 11 NMPA (36.4%) bound C3; and none of the CPA bound C3 in the presence of C without AS. Three of the 14 MPA (21.4%) bound C4, one of the 1 1 (9.1%) NMPA, and none of the nine CPA in the presence of C alone. All strains that bound C4 (MPA and NMPA) also bound C3 (Table 1) .
Correlation of opsonophagocytosis with immunofluorescence. The opsonic requirements of each strain were determined by noting the log1, reduction of cfu in the presence of PMN, C and AS and in the control tests with PMN and C, PMN plus AS, and C and AS. The AS in each case was rabbit antiserum to the prototype strain of the same immunotype as the test strain. Each of these combinations was scored as opsonophagocytic if there were r 1.0 loglo cfu reduction in 60 min. Each strain was classified as to the minimum constituents required for opsonization. The strains of each classification were then divided as to whether they bound C3 and/or C4 in the immunofluorescence test. Table 1 summarizes the results of opsonization and immunofluorescence for all of the 34 strains tested. They are classified by morphology and origin into MPA, NMPA, and CPA and then by opsonic requirements. For each strain it is indicated whether C3 and C4 were bound either in the presence or absence of 10% rabbit antisera to the homologous immunotype strain. Table 2 summarizes the diversity of opsonic requirements of strains of each morphology or origin. Table 3 shows the correlations of opsonic requirements and C3 binding. It can be seen that of the 14 MPA strains, only those which could be opsonized by C bound C3 when incubated with fresh absorbed human serum. Of these six strains, five of them bound C3 on the surface. The significance of the association of C3 binding and opsoniza- tion of MPA strains by C alone was tested by comparing C3 binding in MPA strains with different opsonic requirements. There was a significant difference in C3 binding between MPA strains opsonized by C alone and MPA strains not opsonizable (P = 0.0 15) as well as between strains opsonized by C alone and all MPA strains not opsonized by C alone (P = 0.003). There were no significant associations with C3 binding and opsonic requirements for NMPA nor CPA strains. Table 4 shows similar correlations for binding of C4. It can be seen in this table that only MPA strains that could be opsonized by C could bind C4, but only three of the six strains of this classification were positive for C4 binding. These three strains were three of the five MPA strains which bound C3. Of the 1 1 NMPA strains, four of them bound C3 but these were from all three groups based on opsonic requirements. None of the CPA strains bound C3 or C4 when incubated in C. There were no significant correlations between opsonic requirements and binding of C4.
These strains were also tested for immunofluorescence in the presence of 10% complement and 10% rabbit antiserum. These results are shown in Table 1 . In these tests 11 of the 14 MPA strains bound C3. Two of the MPA strains, which did bind C3, were two of the five strains which could not be opsonized. Of the 11 NMPA strains, eight bound C3 in the presence of complement and antiserum. Those that did not bind C3 included one strain which could be opsonized by C (218NM) and two which required antiserum for opsonization. Of the I 1 NMPA, six bound C4 in the presence of complement and antiserum and all of these were strains that bound C3. Of the nine CPA strains, seven bound C3 in the presence of complement and antiserum and five of these bound C4. The two strains which did not bind C3 were the two strains requiring AS and C for opsonization. None of the CPA strains could be killed by bacteriolysis in the absence of PMN.
Complement inhibition.
We investigated the complement pathways involved in opsonization of the P. aertlginosa strains to determine if binding of C3 and C4 was reflected in utilization of the classical or alternative complement pathways. In these tests all strains were opsonized by the minimum opsonic requirements that we had determined from previous experiments. These are shown in the column "opsonic requirement" in Table 5 . Complement was present in all tests, but only for those strains which required rabbit antibody for 2 1.0 loglo kill was antiserum of that immunotype added. All strains were tested by inhibiting the alternative complement pathway by incubation of complement with zymosan or inhibition of the classical complement pathway by adding the chelator, EGTA. For analysis, the loglo reduction of cfu in the presence of each inhibitor was compared to the results without inhibitor. For EGTA inhibition studies the diluent was HBSS without magnesium or calcium and the control without inhibitor was performed with the same diluent. We have found that the effect of EGTA can be seen best in this medium. In standard HBSS, chelation with EGTA is often without effect on opsonization whereas in the special HBSS there is a remarkable effect of chelation. This is a change in methods from our previous report. Differences in results from previous studies are attributable to this change in procedure (2) . For zymosan inhibition studies, HBSS with calcium and magnesium was used. The results of the studies of several of the representative strains are shown in Table 5 . Both zymosan and EGTA were potent inhibitors of opsonization of most of the strains.
The immunofluorescent studies demonstrated that among MPA strains, divisions could be correlated with opsonic requirements. Table 5 shows the results of opsonophagocytosis of two representative MPA strains which were able to be opsonized by complement. Chelation with EGTA inhibited the killing of all of these strains and in its presence opsonization of the six MPA and five NMPA strains tested resulted in considerably less than 1.0 loglo reduction of cfu. The two strains shown in Table 5 were also opsonized with normal and C4-deficient guinea pig serum. In opsonophagocytic tests of strains 106M and 127M, the effect of C4-deficient guinea pig serum was similar to that shown for EGTA chelation of human serum. Strain 106M had a log,, reduction of cfu of 1.23 in normal guinea pig serum and 0.27 in C4-deficient guinea pig serum. For strain 127M the results were 1.33 and 0.82, respectively. Not all MPA strains were opsonized poorly by C4 deficient serum.
The degree of inhibition by zymosan was more variable than that with EGTA and, like EGTA inhibition, it was not related to morphology or opsonic requirements. For MPA strains opsonized by complement the inhibition by zymosan was less than EGTA suggesting less opsonic activity was due to the alternative complement pathway, but the variability indicated by the two strains shown in Table 5 indicates this is a strain-specific phenomenon. There was variation within this group as demonstrated by opsonization of strain 106M, which was only slightly inhibited, and 127M in which activity was considerably inhibited by zymosan. Among the six MPA strains opsonized by complement, for three strains opsonic activity of complement was reduced to <0.2 log,, reduction in cfu by zymosan (108M, 1 19M, and 153M) and for two strains (1 15M and 106M) there was some inhibition of killing but significant activity remained (approximately 1.0 loglo reduction of cfu) with zymosan. NMPA strains showed a similar diversity. In Table 5 it can be seen that opsonization of 207 NMPA was similar to the two MPA strains which could be opsonized by C, but 113NM could not be opsonized in C treated with zymosan.
Opsonization of the CPA strains was less affected by zymosan inhibition than the other strains were. The results for two strains are shown in Table 5 . These two as well as the seven other CPA strains were opsonized by zymosan-treated complement. Opsonization of most CPA strains was more inhibited by EGTAchelated complement than by zymosan treatment, but some strains such as 565, which was opsonized by heat-inactivated antiserum alone, were affected very little by complement inactivators. The CPA strains appear to require an intact classical complement pathway for optimul amplification of opsonic anti- ' Abbreviations: C, complement; AS, rabbit antiserum to homologous immunotype; and R, resistant to opsonization by C + AS.
body activity but against certain strains there was still conslderable activity when the classical pathway was inhibited.
DISCUSSION
The role of complement in the opsonization of Pseudomonus aeruginosa has been the subject of a number of previous investigations. These investigations have dealt primarily with CPA strains. Bjornson and Michael (3) showed that "heat labile" factors, presumably complement, were required along with antibody to opsonize P. aeruginosa for phagocytosis by mouse leukocytes. Young and Armstrong (15) showed that the heat labile factor was complement for one strain of P. aeruginosa, and by the use of complement inhibitors demonstrated a requirement for complement components 1-4, for near-optimal opsonization and that EGTA was a potent inhibitor. Young (16) suggested that both the alternative and classical complement pathways lead to significant activation of C3. Bjornson and Michael (4) also demonstrated a role for properden and thus the alternative complement pathway for a CPA strain tested in the absence of antibody. In the presence ofantibody this requirement was abolished.
Peterson et al. (12) studied the opsonization of six strains of P. aeruginosa, measuring the uptake radiolabeled P. aeruginosa into human PMN. Using fresh normal human serum as a source of complement they showed that complement was essential for opsonization. Five strains could be opsonized in the absence of intact classical pathway (using C2 and C4 deficient sera) but at a slower than optimal rate. They found that opsonization via the alternative complement pathway was strain-dependent. Of two strains reported on, opsonization of one was only 30% compared with normal serum but another was opsonized essentially the same in normal and zymosan-treated serum. They showed that the strain which was opsonized in zymosan-treated serum still bound C3 (demonstrated by immunofluorescence). This strain behaved like seven of the nine CPA strains we studied, whose opsonization was not inhibited by zymosan treatment of the opsonic source but bound C3 in the presence of antiserum to an opsonic requirement for C, compared with strains which were resistant to opsonization ( P = 0.01 5) or compared with all strains not opsonized by C alone ( P = 0.003). the homologous immunotype. Another similarity between their study and ours was that they found diversity among their six strains for a requirement of antibody for opsonization. All strains were opsonized by fresh normal human serum containing immunoglobulin and complement. Immunoglobulin-deficient serum was opsonic for two of the six strains. They found no strains opsonized by heat-inactivated serum. In our study in which hyperimmune rabbit serum was utilized as a source of antibody, heat-inactivated antiserum was opsonic for five of nine CPA strains, one of 14 MPA, and three of 1 1 NMPA. Our conclusion is that amplification by complement is not always necessary for opsonization when sera which have opsonic titers of >1: 1000 are tested and is a consequence of very high levels of anti-Pseudomonas antibody unlikely to be found in human sera. Our data confirm the studies of Peterson et al. (12) and others which show the diversity of opsonic requirements among classical strains of P. aertlginosa. We too have shown a similar variability of activation of the alternative and classical complement pathways among these strains. We can now extend these observations to MPA strains and their non-mucoid derivatives which, although showing a similar diversity, also have certain unique properties. It has been demonstrated previously that certain MPA strains are completely resistant to opsonization (2) . This has not been reported to occur with NMPA or CPA strains. Other MPA strains are susceptible to opsonization by complement alone. These strains appear to require an intact classical complement pathway for opsonic activity (as defined by our assay) and within this group there is strain variation as to whether they can be opsonized in the absence of the alternative complement pathway. This is true, too of the NMPA strains derived from MPA strains which show a similar diversity of opsonic requirements and of ability to be opsonized by the two complement pathways.
The diversity of opsonic requirements of P. aeruginosa strains from all sources reported here demonstrates the importance of defining these parameters before undertaking studies of pathogenesis. The use of strains with different requirements could have led to conflicting reports from different laboratories. It is conceivable that a strain which could be opsonized by complement alone in our system would behave differently from a strain which requires antibody for opsonization in animal or isolated organ models. Such studies have not been performed. A recent study using an animal model suggests MPA and NMPA have the same pathogenic potential but the opsonic requirements of the strains were not reported (5) . The pathogenesis and immunology of MPA is a new research endeavor and less is known about these strains than classical non-mucoid strains. The immunodeterminant for stimulation of protective antibody is unknown. We have-shown that for most MPA strains unlike NMPA and CPA strains, antibody to the immunotype antigen is not opsonic. No studies, however, have defined the interaction responsible for opsonization of the rare MPA strains, which can be opsonized by antibody with or without complement. A study by Schwarzmann and Boring (13) suggests the immunodeterminant is the extracellular mucoid material, but the purity of this material was not reported.
The data presented in this report shows that MPA strains can be subdivided into at least two classifications by their ability to bind complement, especially C3 on the surface. This division corresponds to in vitro resistance to opsonization.
We would define the,first classification as strains which bind C3 according to immunofluorescence with antiC3. These strains can be opsonized by complement alone. Those of the second classification are strains which do not bind C3 and are resistant to opsonization by complement alone and the great majority are resistant to opsonization by antibody directed toward the immunotype antigen whether complement is present or not. The relevance of this finding to individuals infected with these strains has not yet been studied. It will be important to look prospectively at patients with CF, who are infected with these strains, from the time of first isolation to see if the strains persist for different lengths of time and if their clinical courses differ. We are in the process of following such patients. Finally, one must be careful in the interpretations of antibody studies of patients infected with MPA strains.
Tests which measure antibody to the immunotype antigen may not reveal information relevant to activity against MPA strains and tests of opsonophagocytosis using fresh patients' sera may demonstrate functional activity which can be accounted for on the basis of complement activity alone.
